We describe two cases of Fabry disease in non-blood-related Japanese men, manifesting recurrent stroke even after the start of enzyme replacement therapy. Both exhibited chronic inflammation and ocular involvement with elevated levels of serum C reactive protein prior to the onset of stroke. We, therefore, suggest the association among persistent inflammation, ocular involvement and recurrent stroke in a certain subset of Fabry disease patients. Both cases received enzyme replacement therapy with no improvement in inflammatory signs or laboratory data. These cases suggest that Fabry disease should be considered in young patients with cryptogenic stroke or CNS manifestations and fever of unknown origin.
Introduction
Anderson-Fabry disease or Fabry disease is an X-linked inborn error of glycosphingolipid metabolism caused by defects in the lysosomal hydrolase, α-galactosidase A (α-Gal) (1) . In affected hemizygotes, the accumulation of glycosphingolipids with terminal α-galactosyl moieties, predominantly globotriaosylceramide (Gb3), occurs primarily in plasma and in the lysosomes of vascular endothelium. The molecular pathology of Fabry disease is characterized by a variety of mutations in the α-Gal gene, including partial gene rearrangements, small deletions and insertions, splice consensus site alterations, and various coding region singlebase substitutions (2) (3) (4) (5) . This leads to major disease manifestations, including angiokeratoma, acroparesthesia, corneal opacities, and progressive vascular disease in the heart, kidneys and brain. Fabry disease is progressive and the quality of life of the patient declines as manifestations progress. Male patients typically die at age 40 to 50. Some female patients show renal or cardiac manifestations and experience relatively early death as well. Recently, however, enzyme replacement therapy (ERT) has become practicable and its benefits have been suggested.
Here, we report two cases of Fabry disease in non-bloodrelated patients who showed unusual clinical manifestations, such as marked inflammatory signs including fever and elevation of inflammatory proteins in the peripheral blood. Both patients had central nervous system (CNS) involvement such as recurrent stroke even after the start of ERT. sodes with painful extremities since before the age of 10, was admitted Miyazaki University Hospital because of the increased frequency of the episodes. The patient's mother was undergoing treatment for end-stage renal failure. Laboratory examination showed an increased white blood cell (WBC) count, erythrocyte sediment rate (ESR), and Creactive protein (CRP). There was no specific abnormality suggesting autoimmune or infectious disease. The clinical course of Case 1 is shown in Fig. 1 . The patient was treated with low-dose oral prednisolone and non-steroidal antiinflammatory drugs (NSAIDs) as an outpatient. Two years later, the patient reported visual disturbance in his left eye. Examination resulted in a diagnosis of ischemic retinopathy. Electrocardiogram (ECG) and cardiac sonography revealed hypertrophic cardiomyopathy. In 1997, the patient was admitted to Miyazaki University Hospital for a detailed examination. Physical examination revealed low-grade fever, mild anemia, systolic heart murmur, hepatomegaly, and pretibial pitting edema. The results of the laboratory examination (Table 1) showed an elevated WBC count, erythrocyte sediment rate (ESR), CRP and acute phase inflammatory proteins. Slightly increased levels of serum cytokines such as tumor necrosis factor-α (TNF-α) (42.8 pg/mL), IL-10 (32.2 pg/mL) and interferon-gamma (48.8 pg/mL) were also noted.
A suspicion of Fabry disease prompted measurement of the levels of α-Gal activity in WBC in the patient's family ( Table 1 ). The patient and his mother had a marked and moderate decrease in the level of α-Gal activity, respectively. The patient's father had normal level. Based on these findings, a diagnosis of Fabry disease was made. Histological analysis of heart, kidney, and skin was subsequently performed and deposition of glycosphingolipid due to Fabry disease was revealed. After obtaining informed consent, the α-Gal cDNA coding region (1290bp) was amplified by polymerase chain reaction and cloned. A single base substitution at nucleotide position 128 (128G-to-A) in the first exon (codon 43) was found. This nucleotide substitution, 128G-to-A, results in a missense mutation, replacement of an aspartic acid for a glycine, G43D.
From April 2000, the patient underwent enzyme replacement therapy (ERT) with recombinant α-Gal, which was supplied by Sumitomo Pharmaceuticals (Osaka) (Fig. 1) . Inflammatory findings such as elevation of CRP did not change after the beginning of treatment. The patient also experienced cerebral infarction ( 
Case 2
A 25-year-old man was admitted to Okayama University Hospital in 2003 to undergo ERT for Fabry disease. He had been diagnosed with Fabry disease at the age of 14 based on electron microscope examination of skin biopsy and a significant decrease in α-Gal activity in WBC. The patient reported repeated febrile episodes with painful extremities in his childhood. The patient recognized visual disturbance in his left eye at the age of 24, and examination resulted in a diagnosis of central retinal artery occlusion. The patient's mother had a moderate decrease in the level of α-Gal activity and both his father and younger sister had normal levels ( Table 1) . His uncle had been diagnosed with Fabry disease and had died at 44 years of age during hemodialysis treatment. Examination at the time of admission revealed a slight fever, angiokeratomas to his lower abdomen and pigmentations on his legs. Central obesity, probably due to long-term administration of low-to moderate-dose oral methylprednisolone, was noted. The patient had taken steroids from his childhood because NSAIDs were ineffective in controlling the pain in his extremities. Chest X-ray, ECG, and echocardiogram showed normal findings. Laboratory examination revealed an elevated WBC count, ESR, and CRP, and a slightly increased level of serum TNF-α (Table 1) . Renal function was normal. After obtaining informed consent, DNA sequence analysis was performed and a single base substitution at nucleotide position 704 (C-to-T) in the exon 5 (codon 235) resulting a missense mutation with the replacement of serine for phenylalanine, S235F, was shown (6) .
T a b l e 1 . L a b o r a t o r y F i n d i n g s , S e r u m Cy t o k i n e s , a n d E n z y me Ac t i v i t i e s a n d Ge n e Mu t at i o n s o f α -g a l a c t o s i d a s e A
ERT with recombinant α-Gal (agalsidase beta, Fabra- (Fig. 3) . Currently, the patient has both left hemiparalysis and speech disturbance. In contrast, renal and cardiac functions remained within the normal range in 2009.
Discussion
Cerebrovascular involvement is a well-known complication of Fabry disease. Multiple explanations exist for the high prevalence of CNS events in Fabry disease. These include deposition of glycosphingolipid in the wall of the small vessels and dolichoectasia of the intracranial arteries
F i g u r e 2 . A: MRI f i n d i n g s i n t h e f i r s t e p i s o d e o f c e r e b r a l i n f a r c t i o n ( Ca s e 1 ) . Hy p e r -i n t e n s e l es i o n wa s o b s e r v e d i n t h e r i g h t t h a l a mu s i n t h e T 2 -we i g h t e d a x i a l s e c t i o n ( a r r o w) . B : MRI f i n d i n g s i n t h e f i r s t e p i s o d e o f c e r e b r a l i n f a r c t i o n ( Ca s e 2 ) . Hy p e r -i n t e n s e l e s i o n s we r e f o u n d i n t h e r i g h t p o n s i n t h e T 2 -we i g h t e d a x i a l s e c t i o n ( a r r o ws ) .

F i g u r e 3 . Cl i n i c a l c o u r s e o f Ca s e 2 .
due to lipid involvement of the vascular smooth muscle (7) . Impairment in cerebrovascular reactivity is derived from autonomic dysfunction and increased platelet activity. Furthermore, cardiogenic embolism or valvular heart disease and hypertrophic cardiomyopathy may also play contributory roles (8) .
There are discrepancies in the reported prevalence of Fabry disease in cryptogenic stroke patients. Rolfs et al reported a high frequency of Fabry disease in a cohort of cryptogenic stroke patients aged between 18 and 55 years, at 4% (28/721 patients) (9), while Wozniak et al investigated a sample of 558 young males with first ischemic stroke and found only one case of Fabry disease among 154 cryptogenic stroke patients, for a prevalence of 0.65% in crypto-genic stroke (10) . As for a cohort study of 2,446 patients from the Fabry Registry, 138 patients experienced stroke during the natural history period, including 86 of 1,234 males (6.9%) and 52 of 1,203 females (4.3%). More than 70% of the patients had their first stroke before any renal or cardiac events, and nearly half of these patients experienced their first stroke before being diagnosed with Fabry disease (11) . Regarding Japanese Fabry patients, there is a report that 10 of 65 patients experienced thrombotic accidents. Among these 10 cases, nine developed brain infarctions including one male patient with the complication of recurrent thrombophlebitis and one female patient who showed central retinal artery occlusion and thrombophlebitis (12) . With respect to the efficacy of ERT for CNS complications in Fabry disease, Moore et al reported that ERT normalized cerebral-vessel compliance and regional cerebral hyperperfusion (13) . Other researchers argued against the beneficial effects of ERT on CNS involvement because the access of infused enzyme to nonvascular endothelial cells is limited (14) . Although clinical interventional studies have not revealed that ERT prevents cerebrovascular events, it is known to delay or ameliorate other manifestations of Fabry disease, such as renal and cardiac function or pain (15, 16) . Such patients, therefore, should be considered for ERT.
There are few reports which discuss the inflammatory findings in patients with Fabry disease (17, 18) . Both of the present cases revealed the laboratory data indicating chronic inflammation, such as increased serum levels of CRP and α1-and α2-globulin. There were no clinical and laboratory findings suggesting rheumatic diseases or infections in these cases during the observation period for more than 10 years. Therefore, the inflammatory signs seen in these patients were considered to be due to Fabry disease itself.
The serum levels of TNF-α were relatively high in both of the present 2 cases. TNF-α is recognized to be related to both systemic and local inflammations in numerous inflammatory diseases such as rheumatoid arthritis. The elevation of TNF-α may have played a role not only in inflammation but also in complications like vascular diseases. However, the mechanism of the elevation of TNF-α in the present 2 cases is not clear. There was a report about 9-year-old boy, who was diagnosed both Fabry disease and tumor necrosis factor receptor-associated periodic syndrome (TRAPS) (19) . TRAPS is one of the auto-inflammatory diseases, which is autosomal dominant because of mutations of TNF receptor superfamily 1A (TNFRSF1A) receptor gene. TRAPS is characterized by episode of fever, myalgia, arthralgia or arthritis, rash, abdominal pain, pleuritis, periorbital edema, and conjunctivitis. These symptoms are somewhat similar to those seen in the present 2 cases. However, neither of these 2 cases had any family history of TRAPS. The reported patient with both Fabry disease and TRAPS had a long symptom-free period to date after ERT. On the contrary, the improvement of inflammatory signs was not seen in the present cases after ERT. Therefore, it was not likely that cases in the present study also have TRAPS. However, it could be informative to examine the TNFRSF1A receptor gene in the present cases, if the opportunity arises.
As for other inflammatory cytokines, Altarescu et al investigated the association between IL-6 polymorphism and/ or CRP levels or polymorphism and severity of cardiovascular involvement in Fabry disease; however, the results did not support their hypothesis (20) . In 36 Fabry disease patients with renal impairment, markers for coagulation activation, fibrinolysis, platelet activation, endothelial activation and acute phase response (including CRP) were studied. Male patients were shown to have elevated levels of soluble tissue factor, markers for coagulation activation. An association between renal function and the severity of disease was also revealed, though the laboratory abnormalities were more likely related to renal insufficiency than to Fabry disease (21) . Therefore, the mechanisms of the inflammation in the present cases with Fabry disease and the correlation between chronic inflammation and vascular endothelial cell damage have not been established and further study is necessary.
In addition, the effectiveness of ERT against the CNS manifestations and inflammation was not apparent in the recent cases. If TNF-α is produced by vascular endothelial cells in Fabry disease, ERT may be able to improve inflammation in patients. One possible explanation for the poor responses to ERT especially for the inflammation is that both cases began to receive ERT when they were older than 25 years after a long history of diseases. Long-term follow-up of younger patients may clarify whether ERT is effective in controlling the inflammation associated with Fabry disease.
Some papers have reported that Fabry disease is misdiagnosed as rheumatoid arthritis, multiple sclerosis (22) , rheumatic fever, fibromyalgia syndrome, dermatomyositis, and so on. Mehta and coworkers reported that the mean time between the onset of symptoms and diagnosis was 13.7 and 16.3 years for males and females, respectively (23) . It is important that general practitioners recognize the signs and symptoms of Fabry disease and suspect it as one of the possible causative diseases of fever of unknown origin.
In conclusion, we report two cases of Fabry disease with recurrent CNS manifestations and continuing inflammation. These cases suggest that Fabry disease should be considered in young patients with cryptogenic stroke or CNS manifestations and fever of unknown origin. Paying more attention to Fabry disease may help to avoid misdiagnosis and start treatment at an earlier stage, making it possible to improve the prognosis of Fabry disease patients.
